+

WO1993007890A1 - Traitement de l'hemophilie - Google Patents

Traitement de l'hemophilie Download PDF

Info

Publication number
WO1993007890A1
WO1993007890A1 PCT/GB1992/001926 GB9201926W WO9307890A1 WO 1993007890 A1 WO1993007890 A1 WO 1993007890A1 GB 9201926 W GB9201926 W GB 9201926W WO 9307890 A1 WO9307890 A1 WO 9307890A1
Authority
WO
WIPO (PCT)
Prior art keywords
factor
haemophilia
subcutaneous injection
patient
human
Prior art date
Application number
PCT/GB1992/001926
Other languages
English (en)
Inventor
George Gow Brownlee
Ann Justine Gerrard
Original Assignee
British Technology Group Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by British Technology Group Ltd. filed Critical British Technology Group Ltd.
Priority to JP5507561A priority Critical patent/JPH07502989A/ja
Priority to EP92921475A priority patent/EP0609293A1/fr
Publication of WO1993007890A1 publication Critical patent/WO1993007890A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Definitions

  • This invention relates to the treatment of haemophilia and is particularly concerned with the administration of factor IX.
  • Factor IX is a component of the blood-clotting mechanism of warm-blooded animals : it is Involved together with many other blood clotting factors in the blood coagulation cascade as reviewed by Furie B. and Furle B. C, Cell, 53, 1988, pages 505-518.
  • Haemophilia B, or Christmas disease is a serious inherited bleeding disorder affecting males and caused by a defect in clotting factor IX. Control of the disease is effected by the need for repeated injections of factor IX concentrate, conventionally obtained from blood donors, although more recent technology (as exemplified by EP-A-195592) allows its preparation by recomblnant DNA technology.
  • Factor IX is known to be a single-chain glycoprotein with a molecular weight of approximately 60,000. It is therefore a sufficiently large molecule to point to the need for direct introduction into the bloodstream. Furthermore quite large doses of factor IX (e.g. of the order of 5,000 international, units) may be required for an adult, for example during surgery. Consequently, factor IX preparations have conventionally been delivered intravenously to patients, either prophylactlcally or in response to bleeding episodes in order to control haemophilia B.
  • factor IX can be delivered by subcutaneous injection with sufficiently rapid transport into the bloodstream in biologically active form and in adequate concentrations for control of haemophilia B.
  • the present invention provides a kit for use in subcutaneous injection comprising factor IX and a pharmaceutically acceptable carrier adapted for delivery of an effective dose of factor IX to a haemophilia B patient by such subcutaneous injection.
  • the invention also provides factor IX for use in the preparation of a composition for subcutaneous injection of factor IX to a haemophilia B patient.
  • the invention further provides a method of treatment of a haemophilia B patient comprising subcutaneous injection of the patient with a composition comprising factor IX.
  • the factor IX employed in the invention may be in the form of a concentrate obtained from blood donors or may have been obtained by recombinant DNA technology.
  • the factor IX is preferably human factor IX for the treatment of human haemophilia B patients, although in principle the invention can be applied to the introduction of human or animal factor IX to other warm-blooded animals with an analogous blood clotting mechanism.
  • the factor IX may be initially supplied as, or made up as, a composition in a pharmaceutically acceptable carrier such as deionised water or physiological saline.
  • solid factor IX in suspension may be employed for administration subcutaneously, allowing slow release into the bloodstream from the site of injection.
  • Other comparatively low molecular weight additives and excipients may be present.
  • the factor IX is preferably substantially free of other blood clotting factors such as flbrinogen, prothrombin, factors VII, VIII, X and XI which may be present in some commercially available sources of factor IX.
  • other blood clotting factors may be removed by standard purification procedures such as passing over an immuno-afflnity column loaded with a monoclonal antibody specific for factor IX as described by Rees et al., EMBO J., 7, 1988, pages 2053-2061.
  • the factor IX conveniently in lyophilised form, and any carrier may be provided separately in a kit with the intention of combining the factor IX and carrier Immediately prior to use. Instructions for calculating the dosage to be delivered dependent on the patient's body weight and the circumstances of injection and appropriate for subcutaneous injection will conventionally be included in such a kit.
  • the factor IX can be delivered subcutaneously either prophylactically or in response to bleeding episodes. It will be apparent that the use of subcutaneous delivery is particularly valuable for prophylaxis where there is a lower dose requirement.
  • Lyophilised human factor IX (available as "Mononine” from Armour Pharmaceutical Company, Kankakee, II., USA) was dissolved in deionised water at concentrations ranging from 10 to 500 international units (i.u.) per ml.
  • Fig. 1 shows the results and indicates that factor IX is transported into the bloodstream via subcutaneous injection and reaches a concentration which is approximately 40% of the concentration reached in plasma after intravenous injection of an equivalent amount of factor IX.
  • Factor IX in the purified samples was quantified by ELISA for antigen essentially as described by Anson et al., Nature, 315, 1985, pages 683-685.
  • Factor IX clotting activity was quantified by the one-step clotting assay of Austen and Rhymes, A Laboratory Manual of Blood Coagulation, 1975, Blackwell Scientific Oxford, page 59. In both cases, pooled normal human plasma was used as the standard.
  • Lyophilised human factor IX as used in Examples 1 and 2 was treated to remove any low molecular weight additives as follows:
  • Step 1 20 i.u. factor IX were dissolved in 2ml delonised water.
  • Step 2 The solution was mlcroconcentrated by centrlfugation for 1 hour and the resulting solution, after an estimated 37% loss (estimated by ELISA), contained 12.6 i.u. in a volume of 85 ⁇ l. Although the concentration of additives in this factor IX solution remains unchanged from that in the initial solution, they were reduced in amounts by a calculated 23.5 fold (i.e. 2000 ⁇ l ⁇ 85 ⁇ l).
  • Step 3 The factor IX solution (12.6 i.u. in 85 ⁇ l) was then diluted to 1ml with physiological saline, to give a solution containing 12.6 i.u. factor IX/ml.
  • mice Two mice were injected intravenously into the tail vein and two mice were injected subcutaneously into the back. In each case the total volume of 100 ⁇ l was injected into a single site.
  • 0.1-0.2 ml blood samples were taken from the tail vein at intervals over two days and the human factor IX in the plasma quantified by ELISA as described above. The results are shown in Fig. 3 and are comparable with those obtained in Figs. 1 and 2 showing that the presence of low molecular weight additives is not a significant contributory factor to the ability of the factor IX to reach the bloodstream.
  • factor IX Factor IX
  • IXMC available from Bio Products Laboratory, Elstree, Herts, UK
  • concentration of 81 international units/ml as determined by ELISA
  • the preparation was believed to further contain low molecular weight additives.
  • 8.1 international units factor IX in 100 ⁇ l was injected into each of four mice. Two mice were injected intravenously into the tail vein and two mice, were injected subcutaneously into the back. In each case the total volume was injected into a single site. 0.1-0.2 ml blood samples were taken from the tail vein at intervals over two days and the human factor IX in the plasma was quantified by ELISA as described above. The results are shown in Fig. 4 and show that factor IX is transported to the bloodstream from a subcutaneous injection site with an efficiency of transport of 25% and 43% depending on the mouse (comparing the results of the subcutaneously injected mice with the average of the two intravenously injected mice).
  • Factor IXA Factor IXA (BPL) 585 i.u./bottle.
  • Reconstituted solution when dissolved in 20ml H 2 O contains per litre not more than: 20g protein, 300 mMoles sodium, 200 mMoles chloride, 50 mMoles phosphate, 60 mMoles citrate, 500 i.u. antithrombin III, 5000 u. heparin; nominal content of factor II 800 u.; factor X 400 u.; factor VII negligible for therapeutic purposes.
  • the recommended concentration for human use (i.v.) was 585 i.u. in 20ml.
  • Factor IX was dissolved to a concentration of 585 i.u. in 10ml of deionised water. An ELISA assay showed that this product in fact contained 89.4 international units/ml (447 ⁇ g/ml).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Le facteur IX est utilisé pour traiter par injection sous-cutanée des patients souffrant de l'hémophilie B.
PCT/GB1992/001926 1991-10-24 1992-10-20 Traitement de l'hemophilie WO1993007890A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP5507561A JPH07502989A (ja) 1991-10-24 1992-10-20 血友病の治療
EP92921475A EP0609293A1 (fr) 1991-10-24 1992-10-20 Traitement de l'hemophilie

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919122609A GB9122609D0 (en) 1991-10-24 1991-10-24 Improvements relating to the treatment of haemophilia
GB9122609.2 1991-10-24

Publications (1)

Publication Number Publication Date
WO1993007890A1 true WO1993007890A1 (fr) 1993-04-29

Family

ID=10703480

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1992/001926 WO1993007890A1 (fr) 1991-10-24 1992-10-20 Traitement de l'hemophilie

Country Status (5)

Country Link
EP (1) EP0609293A1 (fr)
JP (1) JPH07502989A (fr)
AU (1) AU2772092A (fr)
GB (2) GB9122609D0 (fr)
WO (1) WO1993007890A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026750A1 (fr) * 1994-03-31 1995-10-12 Pharmacia Ab Formulation pharmaceutique servant a effectuer l'administration sous-cutanee, intramusculaire ou intradermique du facteur viii ou du facteur ix
WO2001082943A2 (fr) 2000-05-03 2001-11-08 Novo Nordisk A/S Administration sous-cutanee de facteur coagulant vii
US7786070B2 (en) 1997-09-10 2010-08-31 Novo Nordisk Healthcare A/G Subcutaneous administration of coagulation factor VII
EP0710114B2 (fr) † 1993-07-05 2011-03-16 Biovitrum Ab Formulation du facteur viii de coagulation
US20120148557A1 (en) * 2009-08-20 2012-06-14 Ulrich Kronthaler Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0430930A1 (fr) * 1985-03-15 1991-06-05 Btg International Limited Protéine facteur IX
WO1991010439A1 (fr) * 1990-01-19 1991-07-25 Octapharma Ag Solutions stables injectables du facteur viii et du facteur ix

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0430930A1 (fr) * 1985-03-15 1991-06-05 Btg International Limited Protéine facteur IX
WO1991010439A1 (fr) * 1990-01-19 1991-07-25 Octapharma Ag Solutions stables injectables du facteur viii et du facteur ix

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
'DICTIONNAIRE VIDAL' 1990 , EDITIONS DU VIDAL "FACTEUR IX HUMAIN HAUTE PURETÉ" *
MEDLINE ABSTRACT 93002484, GERRARD AJ ET AL.:"SUBCUTANEOUS INJECTION OF FACTOR IX FOR THE TREATMENT OF HAEMOPHILIA B.", &BR J HAEMATOL (ENGLAND) AUG 1992,81(4) P610-3 SEE ABSTRACT *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0710114B2 (fr) † 1993-07-05 2011-03-16 Biovitrum Ab Formulation du facteur viii de coagulation
WO1995026750A1 (fr) * 1994-03-31 1995-10-12 Pharmacia Ab Formulation pharmaceutique servant a effectuer l'administration sous-cutanee, intramusculaire ou intradermique du facteur viii ou du facteur ix
US5925739A (en) * 1994-03-31 1999-07-20 Pharmacia & Upjohn Ab Pharmaceutical formulation for subcutaneous intramuscular or intradermal administration of factor VIII
US7786070B2 (en) 1997-09-10 2010-08-31 Novo Nordisk Healthcare A/G Subcutaneous administration of coagulation factor VII
WO2001082943A2 (fr) 2000-05-03 2001-11-08 Novo Nordisk A/S Administration sous-cutanee de facteur coagulant vii
US20120148557A1 (en) * 2009-08-20 2012-06-14 Ulrich Kronthaler Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders

Also Published As

Publication number Publication date
GB2260702B (en) 1995-09-20
JPH07502989A (ja) 1995-03-30
GB9222012D0 (en) 1992-12-02
EP0609293A1 (fr) 1994-08-10
GB2260702A (en) 1993-04-28
GB9122609D0 (en) 1991-12-04
AU2772092A (en) 1993-05-21

Similar Documents

Publication Publication Date Title
EP0710114B1 (fr) Formulation du facteur viii de coagulation
US6103693A (en) Method for isolation of highly pure von willebrand factor
EP0035202B1 (fr) Procédé pour le fractionnement de plasma de sang
EP0719154B1 (fr) Facteur viii active utilise comme agent therapeutique et procede permettant de traiter une deficience en facteur viii
EP0526544B1 (fr) Emplois therapeutiques de composes de liaison d'actine
EP1755652B1 (fr) Facteur ixa pour le traitement de troubles de saignement
NZ282417A (en) Medicaments containing thrombolytically active proteins and non-heparin anticoagulants
US7557188B2 (en) Methods of treating blood coagulation disorders using a pharmaceutical preparation comprising vWF propeptide
EP0716611B1 (fr) Inhibiteur de l'esterase de c1 pour reduire des lesions du myocarde au cours d'un infarctus du myocarde aigu
US4455300A (en) Fibronectin compositions
Aledort Treatment of von Willebrand's disease
WO1993007890A1 (fr) Traitement de l'hemophilie
WO1997035609A1 (fr) Inhibiteur de la neoformation de vaisseaux sanguins renfermant un inhibiteur du mecanisme d'action du facteur tissulaire
Weiss et al. Survival of transfused factor VIII in hemophilic patients treated with epsilon aminocaproic acid
JPH10504310A (ja) 生物学的に活性な化合物で患者を治療する方法
Clemens et al. Therapeutic effects of antivenom supplemented by antithrombin III in rats experimentally envenomated with Russell's viper (Daboia russelli siamensis) venom
CA2276564A1 (fr) Inhibiteur d'esterase c1 modifie pour bloquer la nocivite du vih
JPH11199508A (ja) 臓器不全治療剤
JPH08295635A (ja) 胎盤血流量改善剤
CA2170739C (fr) Methode pour attenuer la gravite des lesions du myocarde lors de crises cardiaques aigues
JPH0618782B2 (ja) 組織プラスミノーゲン活性化因子製剤
JPH08268910A (ja) プロテインｃの皮下投与のための薬剤
Ewing et al. Heparin for uncontrolled disseminated intravascular coagulation in meningococcal septicaemia
JPH09176041A (ja) α２プラスミンインヒビターを含有するＤＩＣ治療用薬剤
Lundblad et al. Factor IX Concentrates and Thrombosis: Amplification of Thrombotic Potential by Interaction between Material Infused and the Host

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: US

Ref document number: 1994 204203

Date of ref document: 19940307

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1992921475

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1992921475

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1992921475

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载